AVTX
AVTX
NASDAQ · Biotechnology

Avalo Therapeutics Inc

$7.76
+0.06 (+0.78%)
As of Nov 15, 10:34 PM ET ·
Financial Highlights (FY 2026)
Revenue
258.9K
Net Income
-343,489,587
Gross Margin
100.0%
Profit Margin
-132,642.4%
Rev Growth
-85.2%
D/E Ratio
0.03
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 100.0% 100.0% 58.1% 58.1%
Operating Margin -123,601.7% -111,241.6% 21.6% 19.4%
Profit Margin -132,642.4% -126,010.3% 22.3% 22.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 258.9K 1.74M 36.29M 36.66M
Gross Profit 258.9K 1.74M 21.09M 21.30M
Operating Income -319,982,527 -1,940,594,840 7.82M 7.11M
Net Income -343,489,587 -2,083,157,872 8.09M 8.22M
Gross Margin 100.0% 100.0% 58.1% 58.1%
Operating Margin -123,601.7% -111,241.6% 21.6% 19.4%
Profit Margin -132,642.4% -126,010.3% 22.3% 22.4%
Rev Growth -85.2% -85.2% +16.8% -1.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 6.17M 6.17M 45.39M 52.32M
Total Equity 220.35M 220.35M 96.06M 95.40M
D/E Ratio 0.03 0.03 0.47 0.55
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -318,572,177 -2,039,377,143 9.50M 9.77M
Free Cash Flow — — 4.67M 3.24M